Document Type : Original Article

Authors

Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Meningiomas are one of the most common primary brain tumors and the most common intradural spinal tumors. Vascular endothelial growth factor has been demonstrated to play an important role in the stimulation of angiogenesis in many types of cancers. Agents that block the vascular endothelial growth factor pathway, such as bevacizumab, have the capability to decrease vascular permeability. The aim of this study is to evaluate vascular endothelial growth factor expression in meningioma patients.Methods: This retrospective, cross-sectional study used an immunohistochemical method to assess vascular endothelial growth factor expression in meningioma. We randomly chose 83 paraffin-embedded tissue blocks of meningiomas diagnosed during 2015 from the files of the Pathology Laboratory of Al-Zahra Hospital, affiliated with Isfahan University of Medical Sciences, Iran.Results: All of the meningioma samples (100%) were vascular endothelial growth factor-immunoreactive. There was a vascular endothelial growth factor score of 1 in 6 (7.2%) cases, a score of 2 in 54 (65.1%) cases, and score of 3 in 23 (27.7%) cases. A correlation existed between vascular endothelial growth factor score and tumor grade. However, there was no correlation between vascular endothelial growth factor score and age and sex of patients.Conclusion: Our study demonstrated a significant role of vascular endothelial growth factor expression in the pathogenesis of peritumoral brain edema in low- and high-grade meningiomas as well as in recurrence or malignant transformation. Thus, anti-vascular endothelial growth factor agents such as bevacizumab might be useful as a treatment of this condition.

 
1.         Saraf S, McCarthy BJ, Villano JL.Update on meningiomas.Oncologist. 2011;16(11):1604-13. doi: 10.1634/theoncologist.2011-0193.
2.         Schellinger KA, Propp JM, Villano JL, McCarthy BJ.Descriptive epidemiology of primary spinal cord tumors.J Neurooncol. 2008;87(2):173-9.
3.         Mahzouni P, Movahedipour M.An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade.Pathol Res Pract. 2012;208(4):221-4. doi: 10.1016/j.prp.2012.01.009.
4.         Rogers L, Gilbert M, Vogelbaum MA.Intracranial meningiomas of atypical (WHO grade II) histology.J Neurooncol. 2010;99(3):393-405. doi: 10.1007/s11060-010-0343-1.
5.         Rooprai HK, Martin AJ, King A, Appadu UD, Jones H, Selway RP et al. Comparative gene expression profiling of ADAMs, MMPs, TIMPs, EMMPRIN, EGF-R and VEGFA in low grade meningioma.Int J Oncol. 2016;49(6):2309-2318. doi: 10.3892/ijo.2016.3739.
6.         Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.Dan Med J. 2013;60(4):B4626.
7.         Dietrich J, Rao K, Pastorino S, Kesari S.Corticosteroids in brain cancer patients: benefits and pitfalls.Expert Rev ClinPharmacol. 2011;4(2):233-42. doi: 10.1586/ecp.11.1.
8.         Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, et al. Antiangiogenic agents for nonmalignant brain tumors.J NeurolSurg B Skull Base. 2013;74(3):136-41. doi: 10.1055/s-0033-1338262.
9.         Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Nat Rev ClinOncol. 2009;6(4):229-36. doi: 10.1038/nrclinonc.2009.14.
10.       Pfister C, Pfrommer H, Tatagiba MS, Roser F.Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomasin vitro.Br J Cancer. 2012;107(10):1702-13. doi: 10.1038/bjc.2012.459.
11.       Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L. Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.Biomed Res Int. 2015;2015:646853. doi: 10.1155/2015/646853.
12.   Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of tumours of the central nervous system. IARC, Lyon
13.       Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W.Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas.Ann Clin Lab Sci. 2008;38(4):344-51.
14.       Kim BW, Kim MS, Kim SW, Chang CH, Kim OL.Peritumoral brain edema in meningiomas : correlation of radiologic and pathologic features.J Korean Neurosurg Soc. 2011;49(1):26-30. doi: 10.3340/jkns.2011.49.1.26.
15.       Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R.Expression of VEGF and its receptors in different brain tumors.Neurol Res. 2005;27(4):371-7.
16.       VokudaRS, Srinivas BH, Madhugiri VS, Verma SK. Vascular endothelial growth factor as an angiogenicmarker in malignant astrocytoma and oligodendroglioma: An Indian scenario. JJClinDiagn Res. 2017;11(2):EC05-EC07. doi: 10.7860/JCDR/2017/24353.9331.
17.       Weindel K, Moringlane JR, Marmé D, Weich HA.Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?Neurosurgery. 1994;35(3):439-48; discussion 448-9.
18.       Criscuolo GR. The genesis of peritumoralvasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor.Yale J Biol Med. 1993;66(4):277-314.
19.       Plate KH, Breier G, Weich HA, Risau W.Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.Nature. 1992;359(6398):845-8.
20.       Maiuri F, De Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.J Neurooncol. 2007;82(1):63-8.
21.       Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.Neuropathol Appl Neurobiol. 2004;30(2):118-25.
22.       Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63-70. doi: 10.1007/s11060-012-0861-0.
23.       Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187-93. doi: 10.1007/s11060-012-0886-4.
24.       Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C, Knosp E.Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients.Neurosurgery. 2010;67(6):1703-8; discussion 1708. doi: 10.1227/NEU.0b013e3181fb801b.
25.       Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A.Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.Neurosurgery. 1997;40(5):1016-26.
26.       Dharmalingam P, Roopesh Kumar VR, Verma SK. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma.Indian J PatholMicrobiol. 2013;56(4):349-54. doi: 10.4103/0377-4929.125286.
27.       Dvorak HF, Brown LF, Detmar M, Dvorak AM.Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.Am J Pathol. 1995;146(5):1029-39.
28.       Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma.J Endocrinol. 1999;161(1):41-9.
29.       Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.J ClinEndocrinolMetab. 2001;86(2):656-8.